Use of etodolac to treat hyperplasia

Abstract

The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g., human) afflicted with excessive tissue growth, an effective amount of a derivative of an indole compound of formula (I):formula (I): wherein R1 is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4 and R5 are the same or different and are each hydrogen or lower alkyl; each R6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R7 is hydrogen, lower alkyl or lower alkenyl, X is oxy and thio, Y is carbonyl, —(CH2)1-3—, —(C1-C3)alkyl(CO)—, or —(CH2)1-3SO2—; Z is hydroxy, lower alkoxy, (C2-C4)acyloxy, —N(R8)(R9), phenylamino, (ω-(4-pyridyl)(C2-C4 alkoxy), (ω-((R8)(R9) amino)(C2-C4 alkoxy), an amino acid ester of (ω-(HO)(C2-C4))alkoxy, —N(R8)CH(R8)CO2H, 1′-D-glucuronyloxy, —SO3H, —PO4H2, —N(NO)(OH), —SO2NH2, —PO(OH)(NH2), —OCH2CH2N(CH3)3+, or tetrazolyl; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; n is 0, 1, 2, or 3; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; each alkyl or phenyl group of R1, R2, R3, R4,R5, R6, R7 and Z is optionally substituted with 1, 2, or 3 (C1-C4)alkyl groups; or a pharmaceutically acceptable salt thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority of U.S. provisional patent application Ser. No. 60 / 412,193, filed Sep. 19, 2002, which is incorporated by reference herein.GOVERNMENT FUNDING [0002] This invention was made with the assistance of the National Institutes of Health under Grant Nos. AR47360 and GM23200. The U.S. Government has certain rights in this invention.BACKGROUND OF THE INVENTION [0003] Hyperplastic diseases are non-malignant conditions that represent an unmet medical need. Typically, these diseases are characterized by the uncontrolled growth of cells. In many patients these cells are not malignant and the hyperplastic cells do not lead to the development of cancer. Thus, the hyperplastic cells are not treated with the conventional chemotherapeutic agents useful against malignant diseases. [0004] One example of a hyperplastic disease is benign prostatic hypertrophy (BPH). This disease is characterized by the abnormal growth of the p...

AI Technical Summary

Benefits of technology

[0015] In another embodiment, the compound of formula (I) is etodolac, R(−)-etodolac, or an analog thereof, effective to inhibit or control the growth of the hyperplastic cells of said mammal. The viability of the hyperplastic cells is reduced selectively, while maintaining the viability of normal cells.

[0017] The present invention also provides a method of increasing the susceptibility of human hyperplastic cells to a chemotherapeutic agent comprising contacting the cells with an effective sensitizing amount of a compound of formula (I), e.g., etodolac, or an analog thereof.

[0018] Further it is applicants' belief that the present invention can provide a synergistic effect when an effective amount of a compound of formula (I), e.g., etodolac, or an analog thereof is administered in combination with a chemotherapeutic agent.

[0021] The present invention is based on the discovery by the inventors that a compound of formula (I), such as, for example, R-etodolac reduces the overall size of the prostates of mice treated with these compounds. The treated mice were found to have prostates that had a reduction of the overall size of the prostates when compared to untreated mice.

Problems solved by technology

Thus, the hyperplastic cells are not treated with the conventional chemotherapeutic agents useful against malignant diseases.

In many patients, hyperplastic diseases do not lead to the development of cancer, and are not treated with the conventional chemotherapeutic agents used against malignant diseases.

Images